


Opening to the Policy Brief Webinar:

**Strengthening Antimicrobial Stewardship: Policy Insights from COVID-19 and
Future Pandemic Preparedness**


By: Dr Viviana Munoz



SPEAKERS


Dr. Rasha Abdelsalam Elshenawy

- Dr. Rasha Abdelsalam Elshenawy is a consultant in antimicrobial resistance (AMR) at the South Centre, Geneva, Switzerland. Since 2018, she has served as the Director of the FADIC Antimicrobial Stewardship School in the UK. She is also working at the University of Hertfordshire, School of Health, Medicine and Life Science. With over 20 years of experience in clinical pharmacy practice, Dr. Elshenawy collaborates globally to advance antimicrobial stewardship strategies. Her primary research focuses on the impact of COVID-19 on antimicrobial resistance and stewardship and public health. She has authored over 150 publications and conference presentations, demonstrating her commitment to addressing the global AMR crisis.



Leveraging Lessons from COVID-19 to Strengthen Antimicrobial Stewardship and Combat AMR

By: Dr Rasha Abdelsalam Elshenawy



The dual pandemics – COVID-19 and antimicrobial resistance (AMR)

How the COVID-19 pandemic disrupted antimicrobial stewardship (AMS) and exacerbated AMR.

Objectives

- Discuss the recent South Centre policy brief on the impact of COVID-19 on antimicrobial stewardship (AMS) and antimicrobial resistance (AMR).
- Highlight key lessons learned from the COVID-19 pandemic.
- Propose policy recommendations to strengthen AMS and address the global threat of AMR.



POLICY BRIEF 136, 25 FEBRUARY 2025

Share this publication on [Twitter](#) [LinkedIn](#) [Facebook](#)

Lessons from COVID-19: Strengthening Antimicrobial Stewardship Prior and During Pandemics

By Dr Rasha Abdelsalam Elshenawy


The COVID-19 pandemic has had a complex impact on the silent pandemic of antimicrobial resistance (AMR). While increased antibiotic misuse and disrupted antimicrobial stewardship (AMS) programs exacerbated AMR in some settings, heightened awareness and improved infection prevention measures implemented to control COVID-19 provided valuable lessons on sustaining these practices in the fight against AMR. This brief highlights lessons learned from the pandemic, such as the importance of access to antimicrobials and the urgent need for resilient and sustainable AMS integrated into pandemic preparedness, strengthening infection prevention and surveillance systems, enhancing access and use of diagnostics, and promoting a One Health approach. By leveraging these lessons, policymakers can build more resilient health systems, maintain the effectiveness of antimicrobials and be better prepared for future pandemics, particularly in developing countries. Immediate action is essential to protect public health and combat AMR effectively.

La pandémie de COVID-19 a eu un impact complexe sur la pandémie silencieuse de la résistance aux antimicrobiens (RAM). Alors que l'augmentation de la mauvaise utilisation des antibiotiques et la perturbation des programmes de gestion des antimicrobiens ont exacerbé la RAM dans certains contextes, la sensibilisation accrue et l'amélioration des mesures de prévention des infections mises en œuvre pour contrôler le COVID-19 ont permis de tirer des enseignements précieux sur le maintien de ces pratiques dans la lutte contre la résistance aux antimicrobiens. Ce document met en lumière les enseignements tirés de la pandémie, tels que l'importance de l'accès aux antimicrobiens et le besoin urgent de programmes de gestion des antimicrobiens résilients et durables, intégrés dans la préparation à la pandémie, le renforcement des systèmes de prévention et de surveillance des infections, l'amélioration de l'accès et de l'utilisation des diagnostics et la promotion d'une approche « Une seule santé ». En tirant parti de ces enseignements, les décideurs politiques peuvent mettre en place des systèmes de santé plus résistants, maintenir l'efficacité des antimicrobiens et être mieux préparés aux futures pandémies, en particulier dans les pays en développement. Il est essentiel d'agir rapidement pour protéger la santé publique et lutter efficacement contre la résistance aux antimicrobiens.

La pandemia de COVID-19 ha tenido un impacto complejo en la pandemia silenciosa de la resistencia a los antimicrobianos (RAM). Mientras que el aumento del uso indebido de antibióticos y la interrupción de los programas de administración de antimicrobianos exacerbaron la RAM en algunos entornos, la mayor concienciación y la mejora de las medidas de prevención de infecciones aplicadas para controlar la COVID-19 proporcionaron valiosas lecciones sobre el mantenimiento de estas prácticas en la lucha contra la RAM. Este informe destaca las lecciones aprendidas de la pandemia, como la importancia del acceso a los antimicrobianos y la necesidad urgente de programas de gestión de antimicrobianos resilientes y sostenibles integrados en la preparación para pandemias, el fortalecimiento de los sistemas de prevención y vigilancia de infecciones, la mejora del acceso y el uso de diagnósticos y la promoción de un enfoque de « Una salud ». Al aprovechar estas lecciones, los responsables políticos pueden construir sistemas de salud más resilientes, mantener la eficacia de los antimicrobianos y estar mejor preparados para futuras pandemias, especialmente en los países en desarrollo. Es esencial actuar de inmediato para proteger la salud pública y combatir eficazmente la RAM.

Download:

[Lessons from COVID-19: Strengthening Antimicrobial Stewardship Prior and During Pandemics](#)



POLICY BRIEF

N° 136
25 February 2025

Lessons from COVID-19: Strengthening Antimicrobial Stewardship Prior and During Pandemics

By Dr Rasha Abdelsalam Elshenawy *

ABSTRACT

The COVID-19 pandemic has had a complex impact on the silent pandemic of antimicrobial resistance (AMR). While increased antibiotic misuse and disrupted antimicrobial stewardship (AMS) programs exacerbated AMR in some settings, heightened awareness and improved infection prevention measures implemented to control COVID-19 provided valuable lessons on sustaining these practices in the fight against AMR. This brief highlights lessons learned from the pandemic, such as the importance of access to antimicrobials and the urgent need for resilient and sustainable AMS integrated into pandemic preparedness, strengthening infection prevention and surveillance systems, enhancing access and use of diagnostics, and promoting a One Health approach. By leveraging these lessons, policymakers can build more resilient health systems, maintain the effectiveness of antimicrobials and be better prepared for future pandemics, particularly in developing countries. Immediate action is essential to protect public health and combat AMR effectively.

KEYWORDS: Antimicrobial Resistance (AMR); Antimicrobial Stewardship (AMS); COVID-19; Pandemic preparedness; One Health approach; Sustainable antimicrobial stewardship; AMR surveillance; Antibiotic resistance.

La pandémie de COVID-19 a eu un impact complexe sur la pandémie silencieuse de la résistance aux antimicrobiens (RAM). Alors que l'augmentation de la mauvaise utilisation des antibiotiques et la perturbation des programmes de gestion des antimicrobiens ont exacerbé la RAM dans certains contextes, la sensibilisation accrue et l'amélioration des mesures de prévention des infections mises en œuvre pour contrôler le COVID-19 ont permis de tirer des enseignements précieux sur le maintien de ces pratiques dans la lutte contre la résistance aux antimicrobiens. Ce document met en lumière les enseignements tirés de la pandémie, tels que l'importance de l'accès aux antimicrobiens et le besoin urgent de programmes de gestion des antimicrobiens résilients et durables, intégrés dans la préparation à la pandémie, le renforcement des systèmes de prévention et de surveillance des infections, l'amélioration de l'accès et de l'utilisation des diagnostics et la promotion d'une approche « Une seule santé ». En tirant parti de ces enseignements, les décideurs politiques peuvent mettre en place des systèmes de santé plus résistants, maintenir l'efficacité des antimicrobiens et être mieux préparés aux futures pandémies, en particulier dans les pays en développement. Il est essentiel d'agir rapidement pour protéger la santé publique et lutter efficacement contre la résistance aux antimicrobiens.

* Dr Rasha Abdelsalam Elshenawy is a Consultant on Antimicrobial Resistance (AMR), South Centre.



Recent releases

→ SouthViews: HRC58 - Neurotechnology

→ Report: Advancing NAPs on AMR amidst Health Financing Challenges

→ SouthViews: International Cooperation under GDC

→ Brief: GDC - equitable future for Developing Countries?

Publications and Pages

Books

Research Papers

Policy Briefs

SouthViews

Previous SouthViews

SouthNews

South Centre News on AMR

Other Publications

WHO Pandemic Treaty & IHR

Publications Catalogues

Main events

→ Webinar: AMS & COVID-19, 14 April 2025

→ South Centre 30th Anniversary

E-mail List Subscription




1. Impact of COVID-19 on Antimicrobial Stewardship

AMR as a Global Health Threat

Current Impact of AMR:


- 1.14 million deaths annually attributed directly to AMR.
- Expected to rise to 10 million deaths per year by 2050.
- Disproportionate impact on LMICs.



AMR as a Global Health Threat

Key Drivers of AMR:

- Unregulated antibiotic use.
- Weak infection prevention and control (IPC).
- Limited access to diagnostics.
- Inadequate antimicrobial stewardship practices.



COVID-19's Impact on AMR and AMS

Increased Antimicrobial Misuse:

- 37–75% of hospitalized COVID-19 patients received antibiotics, despite low bacterial co-infection rates (8–16%).
- Rise in multidrug-resistant organisms (e.g., Carbapenem-resistant *Acinetobacter baumannii*, *Candida auris*).



COVID-19's Impact on AMR and AMS

Disruption of Antimicrobial Stewardship (AMS) Programs:

- AMS audits, reviews, and education deprioritized.
- "AMS fatigue" among prescribers.

Infection Prevention and Control Challenges:

- Overwhelmed hospitals led to lapses in hygiene and IPC.
- Increased healthcare-associated infections (HAIs).



The dual pandemics – COVID-19 and antimicrobial resistance (AMR)

How the COVID-19 pandemic disrupted antimicrobial stewardship (AMS) and exacerbated AMR.


- The pandemic led to increased antibiotic misuse and weakened infection prevention.
- AMR surveillance was compromised, particularly in low- and middle-income countries (LMICs).
- Sustainable AMS must be integrated into pandemic preparedness efforts.
- The One Health approach is critical for tackling AMR across human, animal, and environmental sectors.



2. Lessons from COVID-19 to Strengthen AMS

Lesson 1 – Embedding AMS in Pandemic Response Plans

- **Strengthen AMS frameworks** to prevent antibiotic misuse in emergencies.
- **Integrate AMS into national and global pandemic plans** with clear roles and resources.
- **Enhance real-time surveillance** to track antibiotic use and resistance.
- **Invest in AMS training** for healthcare workers.
- **Ensure equitable access** to antibiotics and stewardship resources globally.



Lesson 2 - Strengthening AMR Surveillance Systems

- **Real-time data sharing** enhances AMR tracking.
- **Leverage technology** (digital dashboards, automated reporting) for surveillance.
- **Strengthen international collaboration** (e.g., GLASS) to improve AMR response.



Lesson 3 – Diagnostics Infrastructure

- **Invest in diagnostics** to improve infection differentiation and reduce antibiotic misuse.
- **Expand point-of-care testing (POCT)** for faster bacterial vs. viral infection identification.
- **Integrate antibiograms** into clinical decision-making.

Organism	Count	Amikacin	Amox/Clav	Amox/Clav	Aztreonam	Cefepime	Cefoxitin	Ceftazidime	Ceftriaxone	Cefurim	Cephalotin	Ciprofloxacin	Gentamicin	Imipenem	Meropenem	Nitrofurantoin	Pip/ Tazo	SXT	Tobramycin
Citrobacter koseri	16	100	20	20	NA	100	30	100	100	NA	20	100	100	100	100	100	100	60	100
Citrobacter freundii	22	100	0	0	NA	82	8	92	92	NA	8	100	100	100	100	92	92	100	100
E.coli	772	64	50	50	NA	50	62	49	47	NA	18	73	83	96	98	82	78	49	74
Enterobacter aerogenes	28	86	9	9	NA	55	13	45	42	NA	0	86	91	98	100	18	88	96	88
Enterobacter cloacae	161	76	18	18	NA	42	4	37	37	NA	4	95	64	89	90	60	59	57	62
Klebsiella oxytoca	6	100	50	50	NA	94	62	33	30	NA	40	100	100	100	100	50	100	100	96
Klebsiella pneumoniae	478	81	76	76	NA	56	73	50	46	NA	28	86	80	93	95	52	81	58	79
Morganella morganii	10	60	0	0	0	40	40	40	40	NA	0	80	80	60	60	0	80	60	80
Proteus mirabilis	57	83	100	100	NA	40	93	73	71	NA	62	87	80	87	88	5	87	67	78
Providencia stuartii	0	0	0	0	0	40	0	0	0	0	0	0	0	0	0	0	0	0	0
Serratia marcescens	65	59	17	17	NA	40	0	28	24	NA	0	86	79	90	94	6	NA	19	76

Hospital wide Gram Positive (GPC)

Organism	COUNT	Ciprofloxacin	Clindamycin	Erythromycin	Gentamicin	Linezolid	Nitrofurantoin	Oxacillin	Penicillin	TMP-SMX	Synercid	Tetracycline	Vancomycin
Staphylococcus aureus	427	83	83	75	83	100	99	46	8	93	99	73	100
Staphylococcus epidermidis	401	68	45	24	36	100	98	10	1	81	94	64	99
Staphylococcus hominis	202	74	64	20	69	100	98	28	12	80	94	51	100
Staphylococcus haemolyticus	169	19	44	4	16	100	96	4	2	54	100	26	99

Fungal infections

Organism	Isolates	Amphotericin B	Caspofungin	Anidulafungin	Flucanazole	Voriconazole	Fluconazole
Candida albicans	180	96	100	NA	98	100	100
Candida glabrata	25	89	100	NA	94	94	94
Candida parapsilosis	53	100	100	NA	96	100	100
Candida krusei	6	100	100	NA	100	100	100

By: Rasha Abdelsalam Elshenawy, 2025.



Lesson 4 – Rational Antibiotic Use & Training

- **Adhere to evidence-based guidelines** to optimise antibiotic prescribing.
- **Enhance public education** on AMR risks and appropriate antibiotic use.
- **Ensure continuous training** for healthcare professionals on resistance trends and stewardship.
- **Provide updated prescribing tools** (antibiograms, resistance data).
- **Promote equitable access** to medicines and diagnostics worldwide.




Lesson 5 – One Health Approach for AMR Control

- **Strengthen cross-sector collaboration** across human, veterinary, and environmental health.
- **Implement policies on antimicrobial use in agriculture** to curb resistance.
- **Improve data sharing & regulations** for pharmaceutical waste management.
- **Invest in One Health infrastructure** for diagnostics, surveillance, and stewardship.
- **Ensure equitable distribution of AMS resources** to low-resource settings.



Lessons from COVID-19 for Emergency Preparedness



3. Recommendations and Call to Action



Addressing Sustainable Access to Antimicrobials

- Strengthen supply chain resilience for antimicrobials and diagnostics.
- Prevent over-the-counter antibiotic sales through strict regulatory frameworks.



Strengthening AMS in Global Health Policy

- Ensure AMS integration into universal health coverage (UHC) frameworks.
- Scale up AMS education for healthcare professionals and prescribers.



Enhancing Surveillance and Diagnostics

- Standardize AMR reporting in LMICs.
- Expand digital health solutions for real-time AMR monitoring.



Enforcing Regulatory Measures

- Implement strict guidelines for antimicrobial use in human and veterinary medicine.
- Strengthen governance on antimicrobial waste disposal.



Promoting Education and Awareness

- Launch global AMR awareness campaigns.
- Integrate AMS training into medical and pharmacy education.




Advancing Research and Development

- Invest in new antimicrobial therapies and alternative treatments.
- Leverage digital tools to improve AMR data collection and analysis.

Key Recommendations

To Strengthen Antimicrobial Stewardship and maintain emergency preparedness

- Six critical issues need to be prepared.



Conclusion

COVID-19 exposed critical gaps in AMS and AMR surveillance.

Urgent Need for Action

- Strengthen AMS in pandemic preparedness.
- Ensure equitable access to antimicrobials and diagnostics.
- Implement One Health-driven AMR strategies.
- Policymakers, healthcare leaders, and global health organizations must act now to build resilient AMS frameworks and prevent the next AMR crisis.



Reference to the Policy Brief



SOUTH CENTRE

POLICY BRIEF

N° 136
25 February 2025

Lessons from COVID-19: Strengthening Antimicrobial Stewardship Prior and During Pandemics

By Dr Rasha Abdelsalam Elshenawy *

ABSTRACT


The COVID-19 pandemic has had a complex impact on the silent pandemic of antimicrobial resistance (AMR). While increased antibiotic misuse and disrupted antimicrobial stewardship (AMS) programs exacerbated AMR in some settings, heightened awareness and improved infection prevention measures implemented to control COVID-19 provided valuable lessons on sustaining these practices in the fight against AMR. This brief highlights lessons learned from the pandemic, such as the importance of access to antimicrobials and the urgent need for resilient and sustainable AMS integrated into pandemic preparedness, strengthening infection prevention and surveillance systems, enhancing access and use of diagnostics, and promoting a One Health approach. By leveraging these lessons, policymakers can build more resilient health systems, maintain the effectiveness of antimicrobials and be better prepared for future pandemics, particularly in developing countries. Immediate action is essential to protect public health and combat AMR effectively.

KEYWORDS: Antimicrobial Resistance (AMR); Antimicrobial Stewardship (AMS); COVID-19; Pandemic preparedness; One health approach; Sustainable antimicrobial stewardship; AMR surveillance; Antibiotic resistance.

La pandémie de COVID-19 a eu un impact complexe sur la pandémie silencieuse de la résistance aux antimicrobiens (RAM). Alors que l'augmentation de la mauvaise utilisation des antibiotiques et la perturbation des programmes de gestion des antimicrobiens ont exacerbé la RAM dans certains contextes, la sensibilisation accrue et l'amélioration des mesures de prévention des infections mises en œuvre pour contrôler le COVID-19 ont permis de tirer des enseignements précieux sur le maintien de ces pratiques dans la lutte contre la résistance aux antimicrobiens. Ce document met en lumière les enseignements tirés de la pandémie, tels que l'importance de l'accès aux antimicrobiens et le besoin urgent de programmes de gestion des antimicrobiens résilients et durables, intégrés dans la préparation à la pandémie, le renforcement des systèmes de prévention et de surveillance des infections, l'amélioration de l'accès et de l'utilisation des diagnostics et la promotion d'une approche « Une seule santé ». En tirant parti de ces enseignements, les décideurs politiques peuvent mettre en place des systèmes de santé plus résistants, maintenir l'efficacité des antimicrobiens et être mieux préparés aux futures pandémies, en particulier dans les pays en développement. Il est essentiel d'agir rapidement pour protéger la santé publique et lutter efficacement contre la résistance aux antimicrobiens.

* Dr Rasha Abdelsalam Elshenawy is a Consultant on Antimicrobial Resistance (AMR), South Centre.

<https://www.southcentre.int>



SOUTH CENTRE

Home | Issues | Social Development | Health | Policy Brief 136, 25 February 2025

POLICY BRIEF 136, 25 FEBRUARY 2025

Share this publication on [Twitter](#) [LinkedIn](#) [Facebook](#)

Lessons from COVID-19: Strengthening Antimicrobial Stewardship Prior and During Pandemics

By Dr Rasha Abdelsalam Elshenawy

The COVID-19 pandemic has had a complex impact on the silent pandemic of antimicrobial resistance (AMR). While increased antibiotic misuse and disrupted antimicrobial stewardship (AMS) programs exacerbated AMR in some settings, heightened awareness and improved infection prevention measures implemented to control COVID-19 provided valuable lessons on sustaining these practices in the fight against AMR. This brief highlights lessons learned from the pandemic, such as the importance of access to antimicrobials and the urgent need for resilient and sustainable AMS integrated into pandemic preparedness, strengthening infection prevention and surveillance systems, enhancing access and use of diagnostics, and promoting a One Health approach. By leveraging these lessons, policymakers can build more resilient health systems, maintain the effectiveness of antimicrobials and be better prepared for future pandemics, particularly in developing countries. Immediate action is essential to protect public health and combat AMR effectively.

La pandémie de COVID-19 a eu un impact complexe sur la pandémie silencieuse de la résistance aux antimicrobiens (RAM). Alors que l'augmentation de la mauvaise utilisation des antibiotiques et la perturbation des programmes de gestion des antimicrobiens ont exacerbé la RAM dans certains contextes, la sensibilisation accrue et l'amélioration des mesures de prévention des infections mises en œuvre pour contrôler le COVID-19 ont permis de tirer des enseignements précieux sur le maintien de ces pratiques dans la lutte contre la résistance aux antimicrobiens. Ce document met en lumière les enseignements tirés de la pandémie, tels que l'importance de l'accès aux antimicrobiens et le besoin urgent de programmes de gestion des antimicrobiens résilients et durables, intégrés dans la préparation à la pandémie, le renforcement des systèmes de prévention et de surveillance des infections, l'amélioration de l'accès et de l'utilisation des diagnostics et la promotion d'une approche « Une seule santé ». En tirant parti de ces enseignements, les décideurs politiques peuvent mettre en place des systèmes de santé plus résistants, maintenir l'efficacité des antimicrobiens et être mieux préparés aux futures pandémies, en particulier dans les pays en développement. Il est essentiel d'agir rapidement pour protéger la santé publique et lutter efficacement contre la résistance aux antimicrobiens.

La pandemia de COVID-19 ha tenido un impacto complejo en la pandemia silenciosa de la resistencia a los antimicrobianos (RAM). Mientras que el aumento del uso indebido de antibióticos y la interrupción de los programas de administración de antimicrobianos exacerbaron la RAM en algunos entornos, la mayor concienciación y la mejora de las medidas de prevención de infecciones aplicadas para controlar la COVID-19 proporcionaron valiosas lecciones sobre el mantenimiento de estas prácticas en la lucha contra la RAM. Este informe destaca las lecciones aprendidas de la pandemia, como la importancia del acceso a los antimicrobianos y la necesidad urgente de programas de gestión de antimicrobianos resilientes y sostenibles integrados en la preparación para pandemias, el fortalecimiento de los sistemas de prevención y vigilancia de infecciones, la mejora del acceso y el uso de diagnósticos y la promoción de un enfoque de «Una salud». Al aprovechar estas lecciones, los responsables políticos pueden construir sistemas de salud más resilientes, mantener la eficacia de los antimicrobianos y estar mejor preparados para futuras pandemias, especialmente en los países en desarrollo. Es esencial actuar de inmediato para proteger la salud pública y combatir eficazmente la RAM.

Download:
Lessons from COVID-19: Strengthening Antimicrobial Stewardship Prior and During Pandemics

This article was tagged: AMR Surveillance, Antibiotic Resistance, Antimicrobial Resistance (AMR),

KEY MESSAGES

- **A Tale of Two Pandemics:** The COVID-19 pandemic exacerbated AMR through antibiotic shortages, misuse, and weakened infection prevention measures.
- **Surveillance Gaps:** Limited laboratory capacities and reallocation of resources during the pandemic have severely hindered AMR monitoring, especially in low- and middle-income countries (LMICs).
- **Lessons from COVID-19:** Integrating AMS into pandemic preparedness requires universal access to diagnostics and antimicrobials, supported by effective stewardship practices.
- **One Health Approach:** Tackling AMR effectively requires cross-sector collaboration addressing human, animal, and environmental health.
- **Policy Priorities:** Invest in infection prevention, improve access, rationalise antimicrobial use, and ensure sustainable stewardship practices.
- **Global Collaboration:** Strengthening international partnerships and knowledge sharing is essential for effectively combating AMR.
- **Call to Action:** Leverage the lessons from COVID-19 to maintain antibiotic safety and build resilient global health systems.

Recent releases

- SouthViews: HRC58 - Neurotechnology
- Report: Advancing NAPs on AMR amidst Health Financing Challenges
- SouthViews: International Cooperation under GDC
- Brief: GDC - equitable future for Developing Countries?

Publications and Pages

- Books
- Research Papers
- Policy Briefs
- SouthViews
- Previous SouthViews
- SouthNews
- South Centre News on AMR
- Other Publications
- WHO Pandemic Treaty & IHR
- Publications Catalogues

Main events

- Webinar: AMS & COVID-19, 14 April 2025
- South Centre 30th Anniversary

E-mail List Subscription

Email address

6. Advancing Research and Development

The COVID-19 pandemic highlighted the critical need for robust research and development (R&D) to confront AMR. Funding innovation in antimicrobials, vaccines, and diagnostics is essential to address current gaps and future threats. Special emphasis must be placed on ensuring equitable access to these advancements, particularly in developing countries, where disparities in healthcare resources hinder AMR containment.

Adopting innovative approaches in antibiotic research is vital. Combining traditional methods with digital tools facilitates data collection, analysis, and dissemination. Mobile-integrated research tools can be employed for surveys and interviews, enhancing accessibility and efficiency. QR codes and other digital methods can help engage broader healthcare workforces, improving the integration of diverse perspectives in research.

The pandemic also emphasized the importance of leveraging virtual and digital platforms for communication with research populations. Tools like video conferencing and online collaboration platforms allow researchers to maintain momentum and broaden their reach, even during global crises.

To amplify the impact of the research, diverse communication channels must be used. Blogs, community posts, correspondence, research papers, visual abstracts, and infographics effectively engage different audiences. Such multi-faceted dissemination strategies ensure findings are accessible and actionable, fostering collaboration and innovation in the fight against AMR.

COVID-19 - Strengthening Antimicrobial Stewardship

- Ensuring equitable and sustainable access to antimicrobials and diagnostics
- Building resilient systems through sustainable antimicrobial stewardship
- Integrating AMS as a critical component of domestic preparedness
- Strengthening regulations in antimicrobial prescribing and use across sectors.
- Investing in adaptive learning, public engagement, and professional training.
- Experimenting with innovative approaches for antimicrobials, diagnostics, & equitable access.



Thank You

By: Dr Rasha Abdelsalam Elshenawy

@Salam_Rasha



Panel Discussion (30 minutes)




Time (CEST)	Session	Speakers
12:00 – 12:05 pm	Opening	Dr Viviana Muñoz Tellez
12:05 – 12:30 pm	Leveraging Lessons from COVID-19 to Strengthen Antimicrobial Stewardship and Combat AMR	Dr Rasha Abdelsalam Elshenawy
NOW: 12:30 – 01:00 pm	Panel Discussion	Dr Kamini Walia Dr. Nusrat Shafiq



SOUTH CENTRE





Panel Discussion


Panel Discussion (30 minutes)



Time (CEST)	Session	Speakers
12:00 – 12:05 pm	Opening	Dr Viviana Muñoz Tellez
12:05 – 12:30 pm	Leveraging Lessons from COVID-19 to Strengthen Antimicrobial Stewardship and Combat AMR	Dr Rasha Abdelsalam Elshenawy
12:30 – 01:00 pm	Panel Discussion	Dr Kamini Walia Dr. Nusrat Shafiq




Panel Discussion



PANELLISTS:

Dr. Kamini Walia

- Dr Kamini Walia is a senior scientist at the Indian Council of Medical Research (ICMR), leading its Antimicrobial Resistance Initiative. She specialises in AMR surveillance, antimicrobial stewardship, and One Health. With over 20 years of public health experience, she has led key projects in infectious diseases and diagnostics. She previously served as Director of Research and Development at PATH and was a WHO expert on essential diagnostics.




Question 1

Commentary on the Policy Brief

What are the key antimicrobial stewardship lessons learned from the COVID-19 pandemic?



Questions for Dr Kamini



Question 2

What actions should governments prioritize to strengthen AMS?



Questions for Dr Kamini



Question 3

What strategies can be implemented to sustain AMS efforts in low- and middle-income countries (LMICs)?


Questions for Dr Kamini



PANELLISTS:

Dr. Nusrat Shafiq

- Dr Nusrat Shafiq is a Professor at the Clinical Pharmacology Unit, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India, and a former President of the Society for Antimicrobial Stewardship Practices in India. She currently serves as the Principal Investigator for the India Hub of the Consortium of Antimicrobial Optimization Network, supported by the Wellcome Trust.



Question 1

Commentary on the Policy Brief

What are the key antimicrobial stewardship lessons learned from the COVID-19 pandemic?

Questions for Dr. Nusrat



Question 2

What are the key challenges in implementing effective antimicrobial stewardship practices in LMICs

Questions for Dr. Nusrat




Question 3

What strategies do you recommend for optimizing antimicrobial stewardship practices in health emergencies such as COVID-19?

Questions for Dr. Nusrat






Conclusion

Final Closing Question:


What is the most critical takeaway from this discussion for policymakers and healthcare leaders?



Closing for the Policy Brief Webinar:

**Strengthening Antimicrobial Stewardship: Policy Insights from COVID-19 and
Preparing for Future Pandemics**

By: Dr Viviana Munoz



Thank You

